Welcome to LookChem.com Sign In|Join Free

CAS

  • or

849793-90-4

Post Buying Request

849793-90-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

849793-90-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 849793-90-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,9,7,9 and 3 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 849793-90:
(8*8)+(7*4)+(6*9)+(5*7)+(4*9)+(3*3)+(2*9)+(1*0)=244
244 % 10 = 4
So 849793-90-4 is a valid CAS Registry Number.

849793-90-4Relevant articles and documents

MODIFIED PROTEINS AND PROTEIN DEGRADERS

-

, (2021/12/08)

Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

Conformational preferences in a benzodiazepine series of potent nonpeptide fibrinogen receptor antagonists

Keenan, Richard M.,Callahan, James F.,Samanen, James M.,Bondinell, William E.,Calvo, Raul R.,Chen, Lichong,DeBrosse, Charles,Eggleston, Drake S.,Haltiwanger, R. Curtis,Hwang, Shing Mei,Jakas, Dalia R.,Ku, Thomas W.,Miller, William H.,Newlander, Kenneth A.,Nichols, Andrew,Parker, Michael F.,Southhall, Linda S.,Uzinskas, Irene,Vasko-Moser, Janice A.,Venslavsky, Joseph W.,Wong, Angela S.,Huffman, William F.

, p. 545 - 559 (2007/10/03)

Previously, we reported the direct design of highly potent nonpeptide 3- oxo-1,4-benzodiazepine fibrinogen receptor antagonists from a constrained, RGD-containing cyclic semipeptide. The critical features incorporated into the design of these nonpeptides were the exocyclic amide at the 8-position which overlaid the Arg carbonyl, the phenyl ring which maintained an extended Gly conformation, and the diazepine ring which mimicked the γ-turn at Asp. In this paper, we investigate conformational preferences of the 8-substituted benzodiazepine analogues by examining structural modifications to both the exocyclic amide and the seven-membered diazepine ring and by studying the conformation of the benzodiazepine ring using molecular modeling, X-ray crystallography, and NMR. We found that the directionality of the amide at the 8-position had little effect on activity and the (E)-olefin analogue retained significant potency, indicating that the trans orientation of the amide, and not the carbonyl or NH groups, made the largest contribution to the observed activity. For the diazepine ring, with the exception of the closely analogous 3-oxo-2-benzazepine ring system described previously, all of the modifications led to a significant reduction in activity compared to the potent 3-oxo-1,4-benzodiazepine parent ring system, implicating this particular type of ring system as a desirable structural feature for high potency. Energy minimizations of a number of the modified analogues revealed that none could adopt the same low-energy conformation as the one shared by the active (S)-isomer of the 3-oxo-1,4-benzodiazepines and 3-oxo-2- benzazepines. The overall data suggest that the features contributing to the observed high potency in this series are the orientation of the 3-4 amide and the conformational constraint imposed by the seven-membered ring, both of which position the key acidic and basic groups in the proper spatial relationship.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 849793-90-4